Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard Chemotherapy in Small Cell Lung Cancer
NCT00011921Phase 3Unknown
- Sponsor
- EBMT Solid Tumors Working Party
- Start
- Sep 1997
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, paclitaxel, ifosfamide, carboplatin and etoposide phosphate in small cell lung cancer (SCLC) (2 arms), sponsored by EBMT Solid Tumors Working Party. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
epirubicinpaclitaxelifosfamidecarboplatinetoposide phosphate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00011921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011921.